AR121013A1 - Anticuerpos anti-cd40 y composiciones - Google Patents

Anticuerpos anti-cd40 y composiciones

Info

Publication number
AR121013A1
AR121013A1 ARP210100047A ARP210100047A AR121013A1 AR 121013 A1 AR121013 A1 AR 121013A1 AR P210100047 A ARP210100047 A AR P210100047A AR P210100047 A ARP210100047 A AR P210100047A AR 121013 A1 AR121013 A1 AR 121013A1
Authority
AR
Argentina
Prior art keywords
antibodies
compositions
cancer
diseases
activity
Prior art date
Application number
ARP210100047A
Other languages
English (en)
Inventor
Lise Camilla Frhlich
Mikkel Wandahl Pedersen
Klaus Koefoed
Trine Lindsted
Anton Willer
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of AR121013A1 publication Critical patent/AR121013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a anticuerpos anti-CD40 y métodos para usarlos en el tratamiento de enfermedades y afecciones relacionadas con la actividad de la CD40, por ejemplo, el cáncer.
ARP210100047A 2020-01-10 2021-01-08 Anticuerpos anti-cd40 y composiciones AR121013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062959598P 2020-01-10 2020-01-10

Publications (1)

Publication Number Publication Date
AR121013A1 true AR121013A1 (es) 2022-04-06

Family

ID=74191711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100047A AR121013A1 (es) 2020-01-10 2021-01-08 Anticuerpos anti-cd40 y composiciones

Country Status (4)

Country Link
US (1) US20210214454A1 (es)
AR (1) AR121013A1 (es)
TW (1) TW202132348A (es)
WO (1) WO2021140222A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023155845A1 (zh) * 2022-02-16 2023-08-24 上海优替济生生物医药有限公司 人源化抗cd28抗体及其与抗cd40的双特异性抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
KR20180021833A (ko) * 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
JP7038064B2 (ja) * 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
CA3042389A1 (en) * 2016-11-02 2018-05-11 Apexigen, Inc. Anti-cd40 antibodies in combination and methods of use

Also Published As

Publication number Publication date
US20210214454A1 (en) 2021-07-15
TW202132348A (zh) 2021-09-01
WO2021140222A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
JOP20210154B1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
EA201691748A1 (ru) Антитела анти-cd38 для лечения острого лимфобластного лейкоза
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
NI201200171A (es) Anticuerpos hacia gdf8 humano
EA201991214A1 (ru) Антитела против pd-1 и их композиции
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
CO6612271A2 (es) Anticuerpos anti-cd40
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
PE20220562A1 (es) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
BR112015023086A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
CO2021015544A2 (es) Moléculas de unión a cd19 y usos de las mismas
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
BR112015016206A2 (pt) moduladores de ship1 e métodos relacionados com os mesmos
AR121013A1 (es) Anticuerpos anti-cd40 y composiciones
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
FB Suspension of granting procedure